The KV regimen inducing cross-presenting CD8+ cDC1s in TC-1 tumor and in TC-1 and MC-38 tumor-dLNs is in line with published data, showing that CD8+ cDC1s are critical for CTL responses [37], and tumor-dLN cDC1s contribute to CD8+ T-cell priming. This evidence concerns the gene CD8A and neoplasm.